Vaccination with a nucleopeptide (NP 118; amino acids 118 to 132) representing a cytotoxic T-cell epitope of lymphocytic choriomeningitis virus (LCMV) can modulate immunopathology. Immunization with NP 118 protected H-2d mice against intracerebral infection with the LCMV-ARMSTRONG isolate. However, when NP 118-primed H-2d mice were challenged intracerebrally with an intermediate dose (5 x 104 PFU) of the LCMV-DOCILE strain, all mice primed with NP 118 emulsified in incomplete Freund's adjuvant died, whereas unprimed mice survived. Correspondingly, peptide vaccination enhanced specifically the cytotoxic T-cell response, influencing the critical balance between T-cell response and virus spread.
Protection against an acute lymphocytic choriomeningitis virus (LCMV) infection is apparently mediated almost exclusively by cytotoxic T lymphocytes (CTLs) (6, 26) ; the same CTLs may also cause immunopathology (8, 9, 12, 17, 26) . The kinetics of viral spread and the T-cell response are important parameters influencing the outcome of disease (6, 12, 19) . After intracerebral (i.c.) infection, the T-cell immune response is only protective when a great number of T cells are recruited early while relatively few choriomeningeal cells are infected. When virus spreads rapidly and too many choriomeningeal cells are infected, immune T cells cause extensive and therefore lethal immunopathological disease (18) . Because LCMV may cause immune suppression also of the CTL response against itself (so-called high-dose immune paralysis [12] ), mice may survive high doses of LCMV-WE or high doses of LCMV-DOCILE injected i.c. (6, 16, 19) .
Immunization with recombinant vaccinia virus expressing the LCMV glycoprotein (vacc-LCMV-GP) or nucleoprotein (vacc-LCMV-NP) has been shown to protect mice from LCM disease (10, 11, 15) by induction of a protective CTL response. However, under certain circumstances, immunization with vacc-LCMV-GP or vacc-LCMV-NP has been found to aggravate disease, e.g., BALB/c mice infected with a high dose of the LCMV-DOCILE isolate survived except for those immunized with vacc-LCMV-GP or vacc-LCMV-NP (18) .
To evaluate whether priming with a synthetic peptide similarly influenced the immune balance in vivo, we used the nucleoprotein peptide 118 (NP 118) of LCMV that has been defined to be a major immunogenic epitope for CTLs in mice of the H-2d haplotype (20) (21) (22) . The (8, 9, 16) .
The data presented here confirm that vaccination of mice with a peptide emulsified in a relatively mild adjuvant can induce a CTL response (3, 14) and thereby modulates the response to LCMV in a beneficial or exceptionally in a detrimental fashion. These findings are comparable to those found with vaccinia virus recombinant vaccines (18) . To understand the paradoxical effect of vaccination, it has to be stated clearly that LCMV is immunosuppressive in certain circumstances. Early and high i.c. virus titers achieved either by infection with a high virus dose or by injection of a rapidly replicating virus isolate, such as LCMV-DOCILE, overwhelmingly infect choriomeningeal cells and the cells of the immune system; but in addition, they may also cause severe immune suppression that includes the T-cell response against LCMV (5, 12, 17) . Under these circumstances, the antiviral T-cell response is suppressed and can neither A. 
